Complement alternative pathway activation in human nonalcoholic steatohepatitis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Segers, Filip M ^a   Verdam, Froukje J ^a   De Jonge, Charlotte ^a,b   Boonen, Bas ^a   Driessen, Ann ^a   Shiri Sverdlov, Ronit ^a   Bouvy, Nicole D ^a   Greve, Jan Willem M ^b   Buurman, Wim A ^a   Rensen, Sander S ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3C; DECAY ACCELERATING FACTOR; MESSENGER RNA; PROPERDIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT FACTOR D; COMPLEMENT FACTOR H;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; DECAY ACCELERATING FACTOR GENE; DISEASE SEVERITY; FACTOR B GENE; FACTOR D; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; MALE; NONALCOHOLIC FATTY LIVER; POLYMERASE CHAIN REACTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; BIOPSY; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; BIOPSY; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT FACTOR B; COMPLEMENT FACTOR D; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PROPERDIN; RNA, MESSENGER;

EID: 84907833288     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110053     Document Type: Article

References (38)

1. Torres DM, Harrison SA (2008) Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134: 1682-1698.
2. Tilg H, Moschen A (2010) Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology (Baltimore, Md) 52: 1836-1846.
3. Maher J, Leon P, Ryan J (2008) Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology (Baltimore, Md) 48: 670-678.
4. Ricklin D, Lambris JD (2013) Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 190: 3831-3838.
5. Rensen S, Slaats Y, Driessen A, Peutz-Kootstra C, Nijhuis J, et al. (2009) Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 50: 1809-1817.
6. Emlen W, Li W, Kirschfink M (2010) Therapeutic complement inhibition: new developments. Seminars in thrombosis and hemostasis 36: 660-668.
7. Kemper C, Hourcade D (2008) Properdin: New roles in pattern recognition and target clearance. Molecular immunology 45: 4048-4056.
8. Wirthmueller U, Dewald B, Thelen M, Schäfer M, Stover C, et al. (1997) Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. Journal of immunology (Baltimore, Md: 1950) 158: 4444-4451.
9. Nolan K, Reid K (1993) Properdin. Methods in enzymology 223: 35-46.
10. Schwaeble W, Reid K (1999) Does properdin crosslink the cellular and the humoral immune response? Immunology today 20: 17-21.
11. Rensen S, Slaats Y, Nijhuis J, Jans A, Bieghs V, et al. (2009) Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. The American journal of pathology 175: 1473-1482.
12. Rensen SS, Bieghs V, Xanthoulea S, Arfianti E, Bakker JA, et al. (2012) Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PloS one 7: e52411.
13. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
14. Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B (1999) Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. The American journal of gastroenterology 94: 2467-2474.
15. Gauvreau D, Roy C, Tom F-Q, Lu H, Miegueu P, et al. (2012) A new effector of lipid metabolism: complement factor properdin. Molecular immunology 51: 73- 81.
16. Maslowska M, Wang H, Cianflone K (2005) Novel roles for acylation stimulating protein/C3adesArg: A review of recent in vitro and in vivo evidence. Vitamins and hormones 70: 309-332.
17. Kimura Y, Miwa T, Zhou L, Song W-C (2008) Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 111: 732-740.
18. Verdam F, Rensen S, Driessen A, Greve J, Buurman W (2011) Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. Journal of clinical gastroenterology 45: 149-152.
19. Kemper C, Mitchell L, Zhang L, Hourcade D (2008) The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proceedings of the National Academy of Sciences of the United States of America 105: 9023-9028.
20. Somani R, Richardson V, Standeven K, Grant P, Carter A (2012) Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes care 35: 894-899.
21. Utzschneider K, Kahn S (2006) Review: The role of insulin resistance in nonalcoholic fatty liver disease. The Journal of clinical endocrinology and metabolism 91: 4753-4761.
22. Moreno-Navarrete J, Martínez-Barricarte R, Catalán V, Sabater M, Gómez- Ambrosi J, et al. (2010) Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 59: 200-209.
23. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, et al. (2006) Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology (Baltimore, Md) 43: 506-514.
24. Weismann D, Hartvigsen K, Lauer N, Bennett K, Scholl H, et al. (2011) Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478: 76-81.
25. Ahmad SR, Lidington EA, Ohta R, Okada N, Robson MG, et al. (2003) Decayaccelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition. Immunology 110: 258-268.
26. Spiller OB, Criado-Garcia O, Rodriguez De Cordoba S, Morgan BP (2000) Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol 121: 234-241.
27. Tilg H (2010) The role of cytokines in non-alcoholic fatty liver disease. Digestive diseases (Basel, Switzerland) 28: 179-185.
28. Mason J, Yarwood H, Sugars K, Morgan B, Davies K, et al. (1999) Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 94: 1673-1682.
29. Sreekumar R, Rosado B, Rasmussen D, Charlton M (2003) Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology (Baltimore, Md) 38: 244-251.
30. Yesilova Z, Ozata M, Oktenli C, Bagci S, Ozcan A, et al. (2005) Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. The American journal of gastroenterology 100: 842-849.
31. Engström G, Hedblad B, Eriksson K-F, Janzon L, Lindgärde F (2005) Complement C3 is a risk factor for the development of diabetes: A populationbased cohort study. Diabetes 54: 570-575.
32. Naughton M, Botto M, Carter M, Alexander G, Goldman J, et al. (1996) Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. Journal of immunology (Baltimore, Md: 1950) 156: 3051-3056.
33. Wlazlo N, van Greevenbroek MM, Ferreira I, Jansen EJ, Feskens EJ, et al. (2012) Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: The CODAM study. Metabolism 61: 1787-1796.
34. Ricklin D, Hajishengallis G, Yang K, Lambris J (2010) Complement: A key system for immune surveillance and homeostasis. Nature immunology 11: 785- 797.
35. Pan X, Kelly S, Melin-Aldana H, Malladi P, Whitington P (2010) Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade. Hepatology (Baltimore, Md) 51: 2061-2068.
36. Pham BN, Mosnier JF, Durand F, Scoazec JY, Chazouilleres O, et al. (1995) Immunostaining for membrane attack complex of complement is related to cell necrosis in fulminant and acute hepatitis. Gastroenterology 108: 495-504.
37. Roychowdhury S, McMullen M, Pritchard M, Hise A, van Rooijen N, et al. (2009) An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice. Hepatology (Baltimore, Md) 49: 1326-1334.
38. Tosello-Trampont A-C, Landes S, Nguyen V, Novobrantseva T, Hahn Y (2012) Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-a production. The Journal of biological chemistry 287: 40161-40172.